Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials

February saw a sustained pace of partnering and portfolio reshaping across the bioconjugate space, alongside multiple late-stage clinical and regulatory catalysts. On the dealmaking front, Chugai exercised its option to license Araris’ multi-payload linker-payload platform, while Wave regained full rights to its GalNAc-conjugated RNA-editing therapy from GSK and signaled plans to accelerate US FDA engagement. Collaboration activity also broadened beyond classic ADCs with HealZen initiating a cross-border partnership in degrader-antibody conjugates, StarkAge teaming with Gustave Roussy to support senolytics ADC development, and Rakuten Medical signing LOTTE Biologics for the manufacturing of antibody-dye photoimmunotherapy conjugates. Multiple platform and asset licenses underscored continued demand for differentiated formats, including B7-H3 ADC and bispecific/dual-payload ADC agreements with MediLink-Roche and Biocytogen-Acepodia, and proximity-guided multispecific work with InduPro-Lilly. Regulators advanced several programs, including Japan supplement NDA submissions for DATROWAY and PADVEC plus pembrolizumab, and China approval of ENHERTU in second-line HER2-positive gastric/gastroesophageal junction adenocarcinoma cancer. Clinically, first-patient dosing milestones spanned HER2, CD37, PD-L1, CDH17, and PSMA-targeted conjugates, while OPUS-3 initiated evaluation of VAX-31 in previously vaccinated adults. Market activity included Sutro’s 110M financing and Intensity’s reverse split, reflecting continued capital management amid ongoing development.